Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elliot Marseille

Showing results (11-20 of 66) with videos related to

Pageof 7
Sort By:
Lancet (London, England)|June 5, 2002
HIV prevention before HAART in sub-Saharan AfricaElliot Marseille, Paul B Hofmann, James G Kahn
Plos One|February 25, 2022
Updated cost-effectiveness of MDMA-assisted therapy for the treatment of posttraumatic stress disorder in the United States: Findings from a phase 3 trialElliot Marseille, Jennifer M Mitchell, James G Kahn
Plos One|June 2, 2022
Correction: Updated cost-effectiveness of MDMA-assisted therapy for the treatment of posttraumatic stress disorder in the United States: Findings from a phase 3 trialElliot Marseille, Jennifer M Mitchell, James G Kahn
AIDS (London, England)|March 22, 2006
The costs and benefits of private sector provision of treatment to HIV-infected employees in Kampala, UgandaElliot Marseille, Joseph Saba, Sowedi Muyingo, et al.
Clinical Drug Investigation|March 1, 2022
The Costs and Health Benefits of Expanded Access to MDMA-assisted Therapy for Chronic and Severe PTSD in the USA: A Modeling StudyAnton L V Avanceña, James G Kahn, Elliot Marseille
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2011
The cost-effectiveness of HIV prevention interventions for HIV-infected patients seen in clinical settingsElliot Marseille, Starley B Shade, Janet Myers, et al.
BMJ Open|July 13, 2017
Bubble continuous positive airway pressure in the treatment of severe paediatric pneumonia in Malawi: a cost-effectiveness analysisTeresa Bleakly Kortz, Benjamin Herzel, Elliot Marseille, et al.
Plos One|October 14, 2020
The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSDElliot Marseille, James G Kahn, Berra Yazar-Klosinski, et al.
Translational Psychiatry|August 29, 2025
Psilocybin-assisted therapy for treatment-resistant depression in the US: a model-based cost-effectiveness analysisAnton L V Avanceña, Linh Vuong, James G Kahn, et al.
BMC Health Services Research|January 24, 2014
Adult male circumcision in Nyanza, Kenya at scale: the cost and efficiency of alternative service delivery modesElliot Marseille, James G Kahn, Sharone Beatty, et al.
Pageof 7

Showing results (11-20 of 66) with videos related to

Sort By:
Pageof 7
Lancet (London, England)|June 5, 2002
HIV prevention before HAART in sub-Saharan AfricaElliot Marseille, Paul B Hofmann, James G Kahn
Plos One|February 25, 2022
Updated cost-effectiveness of MDMA-assisted therapy for the treatment of posttraumatic stress disorder in the United States: Findings from a phase 3 trialElliot Marseille, Jennifer M Mitchell, James G Kahn
Plos One|June 2, 2022
Correction: Updated cost-effectiveness of MDMA-assisted therapy for the treatment of posttraumatic stress disorder in the United States: Findings from a phase 3 trialElliot Marseille, Jennifer M Mitchell, James G Kahn
AIDS (London, England)|March 22, 2006
The costs and benefits of private sector provision of treatment to HIV-infected employees in Kampala, UgandaElliot Marseille, Joseph Saba, Sowedi Muyingo, et al.
Clinical Drug Investigation|March 1, 2022
The Costs and Health Benefits of Expanded Access to MDMA-assisted Therapy for Chronic and Severe PTSD in the USA: A Modeling StudyAnton L V Avanceña, James G Kahn, Elliot Marseille
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2011
The cost-effectiveness of HIV prevention interventions for HIV-infected patients seen in clinical settingsElliot Marseille, Starley B Shade, Janet Myers, et al.
BMJ Open|July 13, 2017
Bubble continuous positive airway pressure in the treatment of severe paediatric pneumonia in Malawi: a cost-effectiveness analysisTeresa Bleakly Kortz, Benjamin Herzel, Elliot Marseille, et al.
Plos One|October 14, 2020
The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSDElliot Marseille, James G Kahn, Berra Yazar-Klosinski, et al.
Translational Psychiatry|August 29, 2025
Psilocybin-assisted therapy for treatment-resistant depression in the US: a model-based cost-effectiveness analysisAnton L V Avanceña, Linh Vuong, James G Kahn, et al.
BMC Health Services Research|January 24, 2014
Adult male circumcision in Nyanza, Kenya at scale: the cost and efficiency of alternative service delivery modesElliot Marseille, James G Kahn, Sharone Beatty, et al.
Pageof 7